us-china trade negotiations are back in limbo

After weeks of increasing optimism, US President Trump yesterday surprisingly twitted that existing tariffs on the $200bn in Chinese imports will rise from 10% to 25% on Friday and that a 25% tariff will be levied on additional U$ 325 bn of goods.

Highlights:

  • After weeks of increasing optimism, US President Trump yesterday surprisingly twitted that existing tariffs on the $200bn in Chinese imports will rise from 10% to 25% on Friday and that a 25% tariff will be levied on additional U$ 325 bn of goods.
  • As a response, China considers pulling out of talks. However, latest news suggest that the large delegation from China will still go to Washington on Friday, but it remains unclear whether Vice Premier Liu He (China’s lead official in the negotiations) will head the team.
  • Trump clearly wants to raise pressure on China while China said it will not negotiate with a “gun at its head”.
  • Last week, there were speculations that a deal could be struck in the negotiations round scheduled for starting on Friday. While we continue to expect that a deal can be ultimately reached, a “face-saving” solution for China will likely last for longer now.
  • Stock markets were caught by surprise. At the time of writing, the Shanghai Index lost 5.8%, the Shenzhen Index 7.4%. The EuroStoxx50 receded by about 2%.

Download the full publication below

US-CHINA TRADE NEGOTIATIONS ARE BACK IN LIMBO

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.